Show simple item record

AuthorRavindran, Sreenithya
AuthorKuruvilla, Vinitha
AuthorWilbur, Kerry
AuthorMunusamy, Shankar
Available date2017-01-11T06:08:40Z
Publication Date2017-04
Publication NameJournal of Cellular Physiologyen_US
Identifierhttp://dx.doi.org/10.1002/jcp.25598
CitationRavindran, S., Kuruvilla, V., Wilbur, K. and Munusamy, S. (2017), Nephroprotective Effects of Metformin in Diabetic Nephropathy. J. Cell. Physiol., 232: 731–742.
URIhttp://hdl.handle.net/10576/5163
AbstractMetformin, a well-known anti-diabetic agent, is very effective in lowering blood glucose in patients with type 2 diabetes with minimal side-effects. Metformin is also being recommended in the treatment of obesity and polycystic ovary syndrome. Metformin elicits its therapeutic effects mainly via activation of AMP-activated kinase (AMPK) pathway. Renal cells under hyperglycemic or proteinuric conditions exhibit inactivation of cell defense mechanisms such as AMPK and autophagy, and activation of pathologic pathways such as mammalian target of rapamycin (mTOR), endoplasmic reticulum (ER) stress, epithelial-to-mesenchymal transition (EMT), oxidative stress, and hypoxia. As these pathologic pathways are intertwined with AMPK signaling, the potential benefits of metformin therapy in patients with type 2 diabetes would extend beyond its anti-hyperglycemic effects. However, since metformin is eliminated unchanged through the kidneys and some studies have shown the incidence of lactic acidosis with its use during severe renal dysfunction, the use of metformin was contraindicated in patients with renal disease until recently. With more studies indicating the relatively low incidence of lactic acidosis and revealing the additional benefits with metformin therapy, the US FDA has now approved metformin to be administered in patients with established renal disease based on their renal function. The purpose of this review is to highlight the various mechanisms by which metformin protects renal cells that have lost its functionality in a diabetic or non-diabetic setting and to enlighten the advantages and therapeutic potential of metformin as a nephroprotectant for patients with diabetic nephropathy and other non-diabetic forms of chronic kidney disease.
SponsorQatar National Research Fund (a member of The Qatar Foundation); NPRP 7-1189-3-304 Office of Academic Research, Qatar University; QUUG-CPH-CPH-12/13-1
Languageen
PublisherWiley
SubjectMetformin
SubjectDiabetic Nephropathy
SubjectAMPK
SubjectER Stress
SubjectAutophagy
TitleNephroprotective Effects of Metformin in Diabetic Nephropathy
TypeArticle
Pagination731-742
Issue Number4
Volume Number232
dc.identifier.essn 1097-4652


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record